PT1453487E - Forma de dosagem farmacêutica com revestimentos múltiplos - Google Patents

Forma de dosagem farmacêutica com revestimentos múltiplos Download PDF

Info

Publication number
PT1453487E
PT1453487E PT01995903T PT01995903T PT1453487E PT 1453487 E PT1453487 E PT 1453487E PT 01995903 T PT01995903 T PT 01995903T PT 01995903 T PT01995903 T PT 01995903T PT 1453487 E PT1453487 E PT 1453487E
Authority
PT
Portugal
Prior art keywords
coating layer
poly
methacrylic acid
methyl methacrylate
outer coating
Prior art date
Application number
PT01995903T
Other languages
English (en)
Inventor
Gregory Paul Dittmar
Joseph Michael Amante
Tony Ryan Cronk
Daniel Gary Newby
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32823137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1453487(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PT1453487E publication Critical patent/PT1453487E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT01995903T 2001-11-23 2001-11-23 Forma de dosagem farmacêutica com revestimentos múltiplos PT1453487E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/043893 WO2003045356A1 (en) 2000-11-20 2001-11-23 Pharmaceutical dosage form with multiple coatings

Publications (1)

Publication Number Publication Date
PT1453487E true PT1453487E (pt) 2008-05-13

Family

ID=32823137

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01995903T PT1453487E (pt) 2001-11-23 2001-11-23 Forma de dosagem farmacêutica com revestimentos múltiplos

Country Status (15)

Country Link
EP (1) EP1453487B2 (pt)
JP (1) JP4999037B2 (pt)
CN (1) CN1314390C (pt)
AT (1) ATE389389T1 (pt)
AU (1) AU2002226955B2 (pt)
BR (1) BRPI0117180B8 (pt)
DE (1) DE60133319T3 (pt)
DK (1) DK1453487T3 (pt)
ES (1) ES2301575T5 (pt)
HU (1) HU231030B1 (pt)
IL (1) IL161628A (pt)
MX (1) MXPA04004747A (pt)
NZ (1) NZ532564A (pt)
PT (1) PT1453487E (pt)
WO (1) WO2003045356A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
GB2407501A (en) * 2003-11-03 2005-05-04 Ist Superiore Sanita Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
KR20080085924A (ko) * 2004-09-01 2008-09-24 더 프록터 앤드 갬블 캄파니 5-아미노-2-하이드록시벤조산 및 환원당을 함유하는 조성물
BRPI0611492B1 (pt) 2005-05-31 2021-10-13 Mars, Incorporated Bifidobactéria probiótica felina
CA2609617C (en) 2005-05-31 2014-07-08 The Iams Company Feline probiotic lactobacilli
PL2124966T3 (pl) 2007-02-01 2016-01-29 Iams Europe B V Sposób zmniejszania reakcji zapalnej i stresu u ssaków za pomocą antymetabolitów glukozy, awokado lub ekstraktów awokado
CA2687130C (en) * 2007-05-07 2017-10-03 Evonik Roehm Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
JP2012107058A (ja) * 2012-02-27 2012-06-07 Warner Chilcott Co Llc 複数のコーティングを有する医薬剤形
US20140141075A1 (en) * 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
GB2510754B (en) * 2013-02-12 2016-07-13 Diurnal Ltd Controlled drug release
PT2959892T (pt) * 2013-02-22 2020-12-15 Zeria Pharm Co Ltd Comprimido com revestimento entérico
JP6165022B2 (ja) * 2013-10-30 2017-07-19 株式会社ファンケル 放出制御型ソフトカプセル剤
WO2016001843A1 (en) * 2014-06-30 2016-01-07 Sun Pharmaceutical Industries Limited Extended-release gastroretentive tablets of voglibose
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
CN107661370A (zh) * 2017-11-20 2018-02-06 贵州浩诚药业有限公司 一种苦参片及其制备方法
CA3098604A1 (en) * 2018-05-03 2019-11-07 M.W. Encap Limited Dosage forms for delivery of medicines to the lower gastrointestinal tract
EP3613414A1 (de) 2018-08-24 2020-02-26 Dr. Falk Pharma Gmbh Pellets mit mehrschichtiger struktur zur verzögerten freisetzung des wirkstoffs im distalen kolon
BR112021022769A2 (pt) * 2019-05-15 2022-01-11 Evonik Operations Gmbh Processo para preparar cápsulas de invólucro duro cheias com revestimentos à base de copolímero de (met)acrilato com uma máquina de enchimento de cápsulas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
CN1239425A (zh) * 1996-11-15 1999-12-22 普罗克特和甘保尔公司 供结肠释放的具有多层肠溶聚合物包衣的药剂
AU5310898A (en) * 1996-12-20 1998-07-17 Dumex-Alpharma A/S Release-controlled coated tablets

Also Published As

Publication number Publication date
AU2002226955A1 (en) 2003-06-10
NZ532564A (en) 2006-06-30
AU2002226955B2 (en) 2006-04-27
HUP0402230A2 (hu) 2005-02-28
EP1453487A1 (en) 2004-09-08
BRPI0117180B1 (pt) 2018-12-04
DK1453487T3 (da) 2008-07-21
ES2301575T3 (es) 2008-07-01
CN1314390C (zh) 2007-05-09
ES2301575T5 (es) 2022-04-22
IL161628A0 (en) 2004-09-27
CN1558754A (zh) 2004-12-29
IL161628A (en) 2014-03-31
HUP0402230A3 (en) 2008-04-28
MXPA04004747A (es) 2004-08-02
JP2005510539A (ja) 2005-04-21
HU231030B1 (hu) 2019-12-30
DE60133319T3 (de) 2021-08-05
BR0117180A (pt) 2004-11-03
EP1453487B1 (en) 2008-03-19
DE60133319D1 (de) 2008-04-30
EP1453487B2 (en) 2021-03-31
ATE389389T1 (de) 2008-04-15
BRPI0117180B8 (pt) 2021-05-25
JP4999037B2 (ja) 2012-08-15
WO2003045356A1 (en) 2003-06-05
DE60133319T2 (de) 2009-04-30

Similar Documents

Publication Publication Date Title
CA2359812A1 (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
IL161628A0 (en) Pharmaceutical dosage form with multiple coatings
EP1275381A4 (en) SOLID COATED PREPARATIONS WITH TEMPERATURE RELEASE FOR ORAL ADMINISTRATION
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
WO2004108162A3 (en) Controlled release pharmaceutical composition
ATE374601T1 (de) Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte peptid- oder protein- wirkstoffe, sowie ein verfahren zur herstellung der arzneiform
RS20070511A (en) Modified release pharmaceutical compositions and processes thereof
HRP20040323C1 (hr) Oralni oblici davanja propiverina ili njegovih farmaceutski prihvatljivih soli s produljenim oslobađanjem djelotvone supstance
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
WO2006058249A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
CA2238271A1 (en) Pharmaceutical compositions comprising flurbiprofen
CA2277365A1 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
WO2003039436A3 (es) Composiciones farmaceuticas que contienen oxibutinina
DE60126433D1 (de) Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
WO2004002445A3 (en) Novel floating dosage form
CA2143413A1 (en) Local Drug Delivery Film, for Periodontal Treatment
EP0497956B1 (en) Controlled release formulations
ATE375789T1 (de) Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel
CA2415957A1 (en) Dry powder formulation comprising racecadotril
CN108338976A (zh) 一种硝苯地平双层渗透泵片及其制备方法
CA2444814A1 (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US20200323834A1 (en) Hydrophobic acid addition salts and pharmaceutical formulations thereof
CA2472449A1 (en) Pharmaceutical composition for oral use with improved absorption
AR060039A1 (es) Formulaciones novedosas